GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: This is a small molecule selective estrogen receptor α (ERα) degrader (SERD) that was designed for potential to target breast cancer metastases in the brain [2]. Structurally it is a derivative of Zentalis Pharmaceuticals' lead candidate SERD ZN-c5 (in phase 1/2 development for primary breast cancer). Preclinical analyses show that this derivative can cross the blood-brain barrier and is orally bioavailable. It is one of the ER modulators that are claimed in a patent issued to Recurium Ip Holdings [1].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Zhang G, Huang PQ, Bunker KD, Hedge SG. (2022)
Estrogen receptor modulators. Patent number: WO2022140744A1. Assignee: Recurium Ip Holdings, Llc. Priority date: 17/12/2021. Publication date: 30/06/2022. |
2. Zhang G, Huang PQ, Bunker KD, Hegde SG, Ma J, Lee CC, Samatar AA, Unni A, Al-Amin M, Kakarla R. (2025)
Discovery of an Orally Bioavailable and Brain Penetrant Selective Estrogen Receptor Degrader. J Med Chem, [Epub ahead of print]. [PMID:40393772] |